Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13311)	1/14/1998 3:21:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

Henry, I'm getting a bit confused here. My current understanding is that Targretin is effective vs. both prostate cancer and breast cancer (lung cancer stabilization as well). Targetin is in P2 trials for prostate cancer, correct? As far as breast cancer goes, however, while Panretin is in trials with Tamoxifenfor breast cancer, Targetin is not in any trials for breast cancer, but in compassionate use has demonstrated effectiveness as a single agent in advanced cases of breast cancer? Is that your understanding? I know you weren't at H and Q, so if you don't have all this info, its ok. I would agree off label use is likely. Either we are missing something or the market is completely off base on LGND.